Aldosterone in Diabetic Nephropathy

Phase 4

• Conditions: Diabetic Nephropathy
• Interventions: Drug: Placebo; Drug: Spironolactone

• Registration Number: NCT00870402
• Lead Sponsor: Universidad de los Andes, Chile

Brief Summary

The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.

Detailed Description

Not available

Study Timeline

• Status Verified: 2009-03
• Study Start: 2009-03
• Study First Submitted: 2009-03-25
• Study First Submitted QC: 2009-03-25
• Last Update Submitted: 2009-03-25
• Study First Posted: 2009-03-27
• Last Update Posted: 2009-03-27
• Primary Completion: 2009-12
• Study Completion: 2010-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

• Diabetic subjects with maximum ten years after diagnostic
• Diabetic nephropathy with albuminuria
• Normal renal function
• Diastolic disfunction
• Taking a IECA or ARA drug family previously

Exclusion Criteria

• Diabetics subjects with macroangiopathy
• Acute coronary syndrome in the three months before
• Hyperkalemia > 5.5 mEq/L
• Pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	Placebo	-
1	Spironolactone	-

Primary Outcome Measures

Name	Time	Method
Reduction of albuminuria	9 months

Secondary Outcome Measures

Name	Time	Method
Reduction of diastolic disfunction	9 months

Trial Locations

Locations (1)

University of Los Andes; 🇨🇱 Santiago, Chile